Venous thromboembolism in the elderly: A narrative review. 2017

T Tritschler, and D Aujesky
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: tobias.tritschler@insel.ch.

Persons aged ≥65years not only account for over 60% of venous thromboembolism (VTE) events, they have also a higher mortality and VTE-related morbidity than younger patients, including anticoagulation-related bleeding and the postthrombotic syndrome. However, only few studies have focused specifically on VTE in older persons and practice guidelines commonly extrapolate study results from younger healthier patients to the multimorbid elderly. Evidence suggests that the clinical presentation is more subtle in the elderly with VTE and that commonly used diagnostic modalities, including clinical prediction rules, D-dimer tests, and planar ventilation-perfusion scans are less specific and efficient in older persons. Moreover, because preventive and therapeutic anticoagulation trials often exclude elderly multimorbid patients who have an increased risk of bleeding, the optimal prophylactic approach in medical inpatients and the best therapeutic anticoagulation strategy in patients with confirmed VTE are uncertain in such patients. In this narrative review, we summarize the evidence on the risk, prevention, diagnosis, treatment, and prognosis of VTE in older patients. We also propose a research agenda to increase the evidence basis on VTE in older patients to optimize their quality of care. Given the fact that the incidence of elderly persons with VTE is likely to rise, future VTE research should attempt to enroll elderly multimorbid patients into pragmatic clinical trials and to increasingly incorporate patient-centered universal outcomes, such as health-related quality of life, functional status, symptom burden, and active life expectancy.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D054556 Venous Thromboembolism Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolism, Venous

Related Publications

T Tritschler, and D Aujesky
February 2022, Research and practice in thrombosis and haemostasis,
T Tritschler, and D Aujesky
February 2011, Thrombosis and haemostasis,
T Tritschler, and D Aujesky
January 2022, Frontiers in cardiovascular medicine,
T Tritschler, and D Aujesky
August 2012, Hospital practice (1995),
T Tritschler, and D Aujesky
September 2021, Seminars in thrombosis and hemostasis,
T Tritschler, and D Aujesky
June 2023, Thrombosis research,
T Tritschler, and D Aujesky
June 2021, Annals of palliative medicine,
T Tritschler, and D Aujesky
October 2009, Revue medicale suisse,
Copied contents to your clipboard!